Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study

Xinran Ma,* Ling Li,* Lei Zhang, Xiaorui Fu, Xin Li, Xinhua Wang, Jingjing Wu, Zhenchang Sun, Xudong Zhang, Xiaoyan Feng, Yu Chang, Zhiyuan Zhou, Feifei Nan, Jieming Zhang, Zhaoming Li, Mingzhi Zhang Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis an...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Ma X, Li L, Zhang L, Fu X, Li X, Wang X, Wu J, Sun Z, Zhang X, Feng X, Chang Y, Zhou Z, Nan F, Zhang J, Li Z, Zhang M
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Dove Medical Press 2020-01-01
Saila:Drug Design, Development and Therapy
Gaiak:
apatinib
relapsed or refractory diffuse large b-cell lymphoma
vegfr-2
efficacy
safety
Sarrera elektronikoa:https://www.dovepress.com/apatinib-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell--peer-reviewed-article-DDDT
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak